方法：对 2010 年至 2022 年期间接受抗血管内皮生长因子（vascular endothelial growth factor，VEGF）治疗的新生血管性 AMD 患者进行回顾性研究。患者被分为长期失访组（失访时间超过 6 个月）、短期失访组（失访时间为 2 个月至不足 6 个月）和持续随访组。研究人员对各 ...

Incorporate omega-3s into your diet: Foods like fish have been shown to reduce the risk of macular degeneration. Don’t forget ...

3月12日，哈医大二院眼科为一位在华探亲的患有年龄相关性黄斑变性（AMD）的美籍患者完成抗VEGF治疗跨国注射，这一跨国医疗案例凸显了哈医大二院眼科在眼底病诊疗领域的国际标准化水平。米切尔（Mitchell）今年72岁，长居美国加州，此前被确诊为新生血管性AMD，需要接受每6周一次的定期规范化玻璃体抗VEGF药物注射治疗。此次 ...

Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Clearside Biomedical (CLSD) announced that presentations on the Company’s lead clinical program, CLS-AX in neovascular age-related macular ...

called “KSI-501,” for wet age-related macular degeneration [AMD]. To give you an idea, KSI-501 is a bispecific antibody biopolymer conjugate that simultaneously targets VEGF and the pro ...

Novel drug that inhibits both VEGF-A and Angiopoietin -2 have a promising role in management of wet AMD. Can we lower the risk of getting AMD? Embrace a healthier lifestyle to reduce the risk of ...

Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...

Aflibercept for exudative AMD with persistent fluid on ranibizumab ... in eyes previously treated with other vascular endothelial growth factor ınhibitors. Am J Ophthalmol. 2013;156(1):23 ...